Skip to main content
. 2024 Jul 3;38(4):1823–1828. doi: 10.21873/invivo.13634

Table I. Patient characteristics.

graphic file with name in_vivo-38-1824-i0001.jpg

GC: Gemcitabine+Cisplatin; Gcarbo: Gemcitabine+Carboplatin; EV: Enfortumab Vedotin; Pcarbo: Paclitaxel+Carboplatin; GC: Gemcitabine+Cisplatin; CR: complete response; PR: partial response; SD: stable disease; PD: progressive disease.